Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

NCT ID: NCT06477523

Last Updated: 2024-06-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 57 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-16
• Study Completion Date: 2026-12-31

Brief Summary

Phase Ib/II, open-label, multicentre study to evaluate the efficacy and safety of low-dose radiotherapy (LDRT) combined with AK104 and chemotherapy as first-line treatment for patients with ES-SCLC.

Detailed Description

This trial aims to assess the safety and efficacy of a new therapeutic strategy that combines to low-dose radiotherapy combination With AK104 plus etoposide and carboplatin/cisplatin.

Conditions

SCLC, Extensive Stage

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LDRT+AK104+chemotherapy

AK104(IV, D1) + Cisplatin (IV, D1)/Carboplatin (IV, D1) +Etoposide (IV, D1-D3) were administrated on a 21-day cycle for four cycles. Concurrent LDRT (15 Gy/5f) were conducted from D1-D5 in the first cycle. Then pts received LDRT and AK104 maintenance until loss of clinical benefit or unacceptable toxicity.

Group Type: EXPERIMENTAL

AK104

Intervention Type: DRUG

IV infusion

Etoposide

Intervention Type: DRUG

Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Carboplatin

Intervention Type: DRUG

Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).

low-dose radiotherapy

Intervention Type: RADIATION

The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).

LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy).

Interventions

AK104

IV infusion

Intervention Type: DRUG

Etoposide

Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention Type: DRUG

Carboplatin

Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention Type: DRUG

low-dose radiotherapy

The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).

LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy).

Intervention Type: RADIATION

Other Intervention Names

Cadonilimab; Chemotherapy; Chemotherapy; LDRT

Eligibility Criteria

Inclusion Criteria

• 18 to 80 years old.
• Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
• Histologically or cytologically confirmed diagnosis of ES-SCLC per the Veterans Administration Lung Study Group (VALG) staging system.
• No prior treatment for ES-SCLC.
• Measurable disease, as defined by RECIST v1.1.
• Eastern Cooperative Oncology Group performance status ≤ 1.
• Life expectancy ≥ 3 months.
• Adequate hematologic and end-organ function.
• All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.

Exclusion Criteria

• Symptomatic or actively progressing Central nervous system metastases.
• Uncontrolled carcinomatous meningitis.
• Uncontrolled severe cancer pain
• Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures (once a month or more frequently).
• Uncontrolled or symptomatic hypercalcemia.
• History of autoimmune disease.
• History of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, or idiopathic pneumonia, or evidence of active pneumonia on chest computed tomography (CT) during screening.
• Active Tuberculosis infection.
• Significant cardiovascular disease.
• Major surgical procedure within 28 days prior to enrollment or anticipation of need for major surgical procedure during the course of the study.
• Known additional malignancy that is progressing or requires active treatment.
• Active infection requiring systemic therapy
• Prior allogenic bone marrow transplantation or solid organ transplant.
• Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk for treatment complications.
• Receipt of live attenuated vaccination within 4 weeks prior to the first dose of study treatment, or plan to receive live attenuated vaccine during the study.
• Currently receiving the treatment of hepatitis B virus infection..
• Received approved or under development systematic anti-tumor therapy within 28 days before enrollment
• Previously received immune checkpoint agonists (antibodies to CD137 targets) or immune checkpoint inhibitors (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.) , immune cell therapy and other treatment of any immune mechanism for tumors
• Treatment with systemic immunosuppressive medications within 1 week prior to enrollment..
• Known allergies or intolerant to test drugs or their excipients; or a known history of severe hypersensitivity reactions to other antibodies.
• Women who are pregnant (positive pregnancy test before medication) or breastfeeding.
• Received chest radiation therapy prior to the first dose.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sichuan University

OTHER

Sponsor Role: lead

Responsible Party

You Lu

Doctor of Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

China West Hospital

Chengdu, Sichuan, China

Site Status: RECRUITING

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

YiJun Wu

Role: CONTACT

wuyj01029@163.com

17888841669 ext. +86

Facility Contacts

You Lu, MD

Role: primary

radyoulu@hotmail.com

00862885423571

Zhuoran Yao, MD

Role: backup

yaozhuoran@outlook.com

13261660839

You Lu, MD.

Role: primary

radyoulu@hotmali.com

18980601763 ext. +86

YiJun Wu, MD.

Role: backup

wuyj01029@163.com

17888841669 ext. +86

Other Identifiers

AK104-IIT-027

Identifier Type: -

Identifier Source: org_study_id